146 related articles for article (PubMed ID: 38916169)
21. Severe Joint Involvement in VEXAS Syndrome: A Case Report.
Lacombe V; Kosmider O; Prévost M; Lavigne C; Urbanski G
Ann Intern Med; 2021 Jul; 174(7):1025-1027. PubMed ID: 33780294
[No Abstract] [Full Text] [Related]
22. Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome in the intensive care unit: a case report.
Belicard F; Belhomme N; Bouzy S; Saillard C; Nedelec F; Mear JB; Ardois S; Pastoret C; Reizine F; Camus C; Painvin B
J Med Case Rep; 2023 Jul; 17(1):314. PubMed ID: 37480098
[TBL] [Abstract][Full Text] [Related]
23. Thrombotic manifestations of VEXAS syndrome.
Groarke EM; Dulau-Florea AE; Kanthi Y
Semin Hematol; 2021 Oct; 58(4):230-238. PubMed ID: 34802545
[TBL] [Abstract][Full Text] [Related]
24. Clinical Manifestations in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: A Narrative Review.
Padureanu V; Marinaș CM; Bobirca A; Padureanu R; Patrascu S; Dascalu AM; Bobirca F; Tribus L; Alexandru C; Serboiu C; Dumitrascu C; Musetescu A
Cureus; 2024 Jan; 16(1):e53041. PubMed ID: 38410307
[TBL] [Abstract][Full Text] [Related]
25. A Case of VEXAS: Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic Syndrome With Co-existing DNA (Cytosine-5)-Methyltransferase 3A Mutation Complicated by Localized Skin Reaction to Tocilizumab and Azacitidine.
Estes J; Malus M; Wilson L; Grayson PC; Maz M
Cureus; 2023 Jun; 15(6):e39906. PubMed ID: 37404435
[TBL] [Abstract][Full Text] [Related]
26. VEXAS within the spectrum of rheumatologic disease.
Koster MJ; Warrington KJ
Semin Hematol; 2021 Oct; 58(4):218-225. PubMed ID: 34802543
[TBL] [Abstract][Full Text] [Related]
27. VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease.
Saad AJ; Patil MK; Cruz N; Lam CS; O'Brien C; Nambudiri VE
Exp Dermatol; 2024 Mar; 33(3):e15050. PubMed ID: 38469984
[TBL] [Abstract][Full Text] [Related]
28. A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment.
Tozaki N; Tawada C; Niwa H; Mizutani Y; Shu E; Kawase A; Miwa Y; Ohnishi H; Sasai H; Miyako K; Hosokawa J; Kato A; Kobayashi K; Miyazaki T; Shirakami Y; Shimizu M; Iwata H
Front Med (Lausanne); 2022; 9():1046820. PubMed ID: 36544501
[TBL] [Abstract][Full Text] [Related]
29. Venous and arterial thrombosis in patients with VEXAS syndrome.
Kusne Y; Ghorbanzadeh A; Dulau-Florea A; Shalhoub R; Alcedo PE; Nghiem K; Ferrada MA; Hines A; Quinn KA; Panicker SR; Ombrello AK; Reichard K; Darden I; Goodspeed W; Durrani J; Wilson L; Olteanu H; Lasho T; Kastner DL; Warrington KJ; Mangaonkar A; Go RS; Braylan RC; Beck DB; Patnaik MM; Young NS; Calvo KR; Casanegra AI; Grayson PC; Koster MJ; Wu CO; Kanthi Y; Patel BA; Houghton DE; Groarke EM
Blood; 2024 May; 143(21):2190-2200. PubMed ID: 38306657
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and genetic features of MDS associated with VEXAS syndrome].
Kunimoto H
Rinsho Ketsueki; 2024; 65(4):255-264. PubMed ID: 38684436
[TBL] [Abstract][Full Text] [Related]
31. VEXAS syndrome.
Grayson PC; Patel BA; Young NS
Blood; 2021 Jul; 137(26):3591-3594. PubMed ID: 33971000
[TBL] [Abstract][Full Text] [Related]
32. VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases.
Vitale A; Caggiano V; Bimonte A; Caroni F; Tosi GM; Fabbiani A; Renieri A; Bocchia M; Frediani B; Fabiani C; Cantarini L
Intern Emerg Med; 2023 Apr; 18(3):711-722. PubMed ID: 36662445
[TBL] [Abstract][Full Text] [Related]
33. VEXAS syndrome in a woman.
Barba T; Jamilloux Y; Durel CA; Bourbon E; Mestrallet F; Sujobert P; Hot A
Rheumatology (Oxford); 2021 Nov; 60(11):e402-e403. PubMed ID: 33930131
[No Abstract] [Full Text] [Related]
34. How I diagnose and manage VEXAS syndrome.
Hagiya A; Siddiqi IN; Wang E; Lu CM
Am J Clin Pathol; 2024 Jul; 162(1):28-40. PubMed ID: 38511841
[TBL] [Abstract][Full Text] [Related]
35. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
36. A Case of VEXAS Syndrome Complicated by Hemophagocytic Lymphohistiocytosis.
Grey A; Cheong PL; Lee FJ; Abadir E; Favaloro J; Yang S; Adelstein S
J Clin Immunol; 2021 Oct; 41(7):1648-1651. PubMed ID: 34080084
[No Abstract] [Full Text] [Related]
37. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB; Bodian DL; Shah V; Mirshahi UL; Kim J; Ding Y; Magaziner SJ; Strande NT; Cantor A; Haley JS; Cook A; Hill W; Schwartz AL; Grayson PC; Ferrada MA; Kastner DL; Carey DJ; Stewart DR
JAMA; 2023 Jan; 329(4):318-324. PubMed ID: 36692560
[TBL] [Abstract][Full Text] [Related]
38. Central nervous system vasculitis in VEXAS syndrome: A rare involvemen.
Langlois V; Curie A; Demas A; Etancelin P; Sauvètre G; Leclancher A; Mekinian A
Clin Neurol Neurosurg; 2024 Jul; 242():108351. PubMed ID: 38801808
[TBL] [Abstract][Full Text] [Related]
39. Novel Somatic UBA1 Variant in a Patient With VEXAS Syndrome.
Stiburkova B; Pavelcova K; Belickova M; Magaziner SJ; Collins JC; Werner A; Beck DB; Balajkova V; Salek C; Vostry M; Mann H; Vencovsky J
Arthritis Rheumatol; 2023 Jul; 75(7):1285-1290. PubMed ID: 36762418
[TBL] [Abstract][Full Text] [Related]
40. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis.
Ferrada MA; Savic S; Cardona DO; Collins JC; Alessi H; Gutierrez-Rodrigues F; Kumar DBU; Wilson L; Goodspeed W; Topilow JS; Paik JJ; Poulter JA; Kermani TA; Koster MJ; Warrington KJ; Cargo C; Tattersall RS; Duncan CJA; Cantor A; Hoffmann P; Payne EM; Bonnekoh H; Krause K; Cowen EW; Calvo KR; Patel BA; Ombrello AK; Kastner DL; Young NS; Werner A; Grayson PC; Beck DB
Blood; 2022 Sep; 140(13):1496-1506. PubMed ID: 35793467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
